VCA Stocks

Hercules provides $250,000 direct equity investment to Crux Biomedical, Inc. Crux, a privately held medical device firm, is developing an Inferior Vena Cava (IVC) filter for the treatment and prevention of pulmonary embolism (PE).  “According to Crux Biomedical, approximately 600,000 patients develop a PE every year,” said Brandt Roberts of Hercules. “With no clear leader in the IVC filter market, we recognized a significant business opportunity in supporting Crux’s mission to develop a superior device to treat this prevalent condition. According to Medtech Ventures, the 2006 worldwide market for IVC filters was estimated to be $260 million and growing by eight to ten percent annually. We believe Crux is well positioned to establish a leading presence in this burgeoning market.”